BMS Ownership. Subject to the terms of this Agreement, all BMS Asset Inventions shall be owned solely by BMS, and BMS will have the full right to exploit such BMS Asset Inventions without the consent of, or any obligation to account to, Nektar. Nektar hereby assigns (and shall cause its Affiliates and contractors to assign) all right, title and interest in any BMS Asset Inventions to BMS. The Parties shall execute any documents necessary to accomplish the foregoing assignment, and Nektar shall execute such further documents and provide other assistance as may be reasonably requested by BMS to perfect BMS’s rights in such BMS Asset Inventions, all at BMS’s expense. BMS shall have the sole right but not the obligation to prepare, file, prosecute (including any proceedings relating to reissues, reexaminations, protests, interferences, oppositions, post-grant reviews or similar proceedings and requests for patent extensions) and maintain any BMS Asset Patent Rights or BMS Background Patent Rights at its own expense.

BMS Obligations. Following completion of the Manufacturing technology transfer pursuant to [Section 6.4.2] with respect to Licensed Product(s) Directed to a Collaboration Target, BMS, either directly or through one or more Third Party contract manufacturers, BMS shall have the sole right and responsibility, at its own cost and expense, for all Manufacturing activities necessary for the Development and Commercialization of such Licensed Product(s).

BMS Ownership. Subject to the terms of this Agreement, all BMS Study Inventions and BMS Study Patent Rights shall be owned solely by BMS, and BMS will have the full right to exploit such BMS Study Inventions and BMS Study Patent Rights without the consent of, or any obligation to account to, the Recipient. The Recipient shall assign and hereby assigns (and shall cause its Affiliates and contractors to assign) all its right, title and interest in any BMS Study Inventions and BMS Study Patent Rights to BMS. The Recipient shall execute such further documents and provide other assistance as may be reasonably requested by BMS to perfect BMS’s rights in such BMS Study Inventions and BMS Study Patent Rights, all at BMS’s expense. BMS shall have the sole right but not the obligation to prepare, file, prosecute (including any proceedings relating to reissues, reexaminations, protests, interferences, oppositions, post-grant reviews or similar proceedings and requests for patent extensions) and maintain any BMS Study Patent Rights at its own expense.

BMS Patents. Except as set forth in [Section 8.3.4, BMS]S] shall have the sole right, but not the obligation, to enforce and defend the BMS Background Patents, ​, and BMS Collaboration Patents ​ against any Competitive Infringement worldwide, under its control and at its own expense.

Ownership of Study Data. BMS shall own the Study Data to the extent that it relates solely to the BMS Study Drug (“BMS Study Data”), and Recipient shall own the Study Data to the extent that it relates solely to the Recipient Study Drug (“Recipient Study Data”).

BMS Indemnification. BMS hereby agrees to defend, hold harmless and indemnify (collectively, “Indemnify”) the Recipient, its Affiliates, and its and their agents, directors, officers, employees and subcontractors (the “Recipient Indemnitees”) from and against any and all liabilities, expenses and/or losses,

BMS Ownership. As between the Parties, BMS or an Affiliate of BMS designated by BMS shall own and retain all right, title, and interest in and to any and all BMS Patents (excluding Joint Collaboration Patents) and BMS Know-How (excluding Joint Collaboration Know-How).

BMS Assets. The licenses granted to Nektar in Section 11.2, and the access to BMS Assets provided pursuant to [Section 16.5(d)], shall continue. In addition, if there are any Launched Products (whether existing as of [[Nektar:Organization]] of termination or commercially launched thereafter), ​.

BMS Indemnification. BMS hereby agrees to defend, hold harmless and indemnify (collectively, “Indemnify”) Nektar, its Affiliates, and its and their agents, directors, officers, and employees (the “Nektar Indemnitees”) from and against any and all liabilities,

BMS Assets. During the Term, BMS shall be solely responsible for the Manufacture or having Manufactured all BMS Assets (including all such Manufacturing for use in Clinical Trials, GLP toxicology studies and for commercial sale). ​. All BMS Assets supplied for a Collaboration Study or Independent Study shall have sufficient expiration dates to complete such Collaboration Study or Independent Study. BMS will, if applicable, package, Label and distribute the BMS Assets for use in the Collaboration Studies and Independent Studies.